FNA vs. KIDS, SILK, AORT, ATRI, ATRC, TMCI, MDXG, SIBN, EMBC, and IRMD
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include OrthoPediatrics (KIDS), Silk Road Medical (SILK), Artivion (AORT), Atrion (ATRI), AtriCure (ATRC), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), SI-BONE (SIBN), Embecta (EMBC), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
OrthoPediatrics (NASDAQ:KIDS) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.
OrthoPediatrics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
OrthoPediatrics has a net margin of -14.10% compared to OrthoPediatrics' net margin of -22.11%. Paragon 28's return on equity of -5.03% beat OrthoPediatrics' return on equity.
In the previous week, OrthoPediatrics had 19 more articles in the media than Paragon 28. MarketBeat recorded 23 mentions for OrthoPediatrics and 4 mentions for Paragon 28. Paragon 28's average media sentiment score of 0.48 beat OrthoPediatrics' score of 0.28 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics received 280 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 78.79% of users gave Paragon 28 an outperform vote while only 64.56% of users gave OrthoPediatrics an outperform vote.
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 15.3% of Paragon 28 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
OrthoPediatrics currently has a consensus target price of $45.50, suggesting a potential upside of 37.13%. Paragon 28 has a consensus target price of $17.67, suggesting a potential upside of 85.96%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe Paragon 28 is more favorable than OrthoPediatrics.
OrthoPediatrics has higher earnings, but lower revenue than Paragon 28. OrthoPediatrics is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
Summary
OrthoPediatrics beats Paragon 28 on 11 of the 18 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
